317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

Bibliographic Details
Main Authors:	Leisha Emens, Naomi Hunder, Samuel Klempner, Erika Hamilton, Muralidhar Beeram, Valerie Odegard, Sue Hamke
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Production and Characterization of Anti-Her2 Monoclonal Antibodies
by: A.S. Tabatabaei-Panah, et al.
Published: (2008-01-01)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
by: Dan Zhao, et al.
Published: (2019-05-01)

Investigation of Acoustic Injection on the MPU6050 Accelerometer
by: Yunfan Zhang, et al.
Published: (2019-07-01)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
by: Konstantinos V. Floros, et al.
Published: (2021-02-01)

Production and Characterization of Monoclonal Antibodies Against the Dimerization Domain of Human HER2
by: Nadri, et al.
Published: (2015-07-01)

Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody
by: Mohammad Mehdi Amiri, et al.
Published: (2019-03-01)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
by: Avisek Majumder, et al.
Published: (2021-04-01)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
by: Giulia Bon, et al.
Published: (2020-12-01)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
by: Gonzalez Rachel M, et al.
Published: (2011-02-01)

Heregulin Activates a Novel HER2/HER3-MTK1-GIT1/ERK1/2 MAPK Signaling Pathway
by: Sollome, James Jerome
Published: (2014)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
by: Shengnan Yu, et al.
Published: (2017-11-01)

HER2 signaling regulates HER2 localization and membrane retention.
by: Jaekwang Jeong, et al.
Published: (2017-01-01)

Preclinical HER-2 vaccines: from rodent to human HER-2
by: Pier-Luigi eLollini, et al.
Published: (2013-06-01)

401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
by: Marcin Kowanetz, et al.
Published: (2020-11-01)

Minimal HER1 and HER2 expressions in CHO and HEK-293 cells cause them appropriate negative cells for HERs-related studies
by: Abasalt Hosseinzadeh Colagar, et al.
Published: (2013-11-01)

Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer
by: Abdullah Alajati, et al.
Published: (2015-04-01)

Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.
by: Marianne Hauglid Flågeng, et al.
Published: (2013-01-01)

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
by: Sae-Won Han, et al.
Published: (2012-01-01)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
by: Stenehjem DD, et al.
Published: (2014-10-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

HER2 heterogeneity
by: A. Prat
Published: (2021-04-01)

Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer
by: Sylwia Dębska-Szmich, et al.
Published: (2015-05-01)

Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation
by: Yassamine Lazrek, et al.
Published: (2013-03-01)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.
by: Rocio Vicario, et al.
Published: (2015-01-01)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
by: Hyun Jung Kim, et al.
Published: (2020-05-01)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
by: Alberto Ocaña, et al.
Published: (2020-01-01)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01)

Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.
by: Alejandro Vazquez-Martin, et al.
Published: (2009-01-01)

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
by: Ceran Ceyhan, et al.
Published: (2012-10-01)

Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
by: Harish Shankaran, et al.
Published: (2013-01-01)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
by: James Crespo, et al.
Published: (2020-01-01)

Genome-Wide Investigation of SBT Family Genes in Pineapple and Functional Analysis of AcoSBT1.12 in Floral Transition
by: Xingyue Jin, et al.
Published: (2021-09-01)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
by: Mari Hosonaga, et al.
Published: (2018-07-01)

Investigation of HER2 expression and HER2 related pathway in ovarian mucinous carcinoma
by: Wan-Ru Chao, et al.
Published: (2015)

HER1 R497K and HER2 I655V Polymorphisms Are Linked to Development of Breast Cancer
by: Naglaa R. AbdRaboh, et al.
Published: (2013-01-01)

Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines
by: Tuba Ozbay, et al.
Published: (2011-01-01)

Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines
by: Tuba Ozbay, et al.
Published: (2011-07-01)

Cerium oxide-monoclonal antibody bioconjugate for electrochemical immunosensing of HER2 as a breast cancer biomarker
by: Yeni Wahyuni Hartati, et al.
Published: (2020-02-01)

Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
by: Iago Dilion Lima Cavalcanti, et al.